ResearcherHarbin Medical UniversityActive in the last 2 years
Hengzhen Li
Matched on ORCID iD 0000-0002-1140-3660; OpenAlex author ID A5071401463. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper
Papers 5
- USP15 Promotes Pancreatic Cancer Progression and Cisplatin Resistance By Activating DNA Damage Repair. First author DOI 10.1002/mc.70105↗
- TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1-Mediated Arachidonic Acid Metabolism. Co-author DOI 10.1002/advs.202413674↗
- Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae207↗
- VDR promotes pancreatic cancer progression in vivo by activating CCL20-mediated M2 polarization of tumor associated macrophage. Co-author DOI 10.1186/s12964-024-01578-x↗
- HOXB9 blocks cell cycle progression to inhibit pancreatic cancer cell proliferation through the DNMT1/RBL2/c-Myc axis. Co-author DOI 10.1016/j.canlet.2022.215595↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Xiaona Fan · 3 shared papers, 2024–2025 · strength 0.55
- Paper TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1-Mediated Arachidonic A… DOI 10.1002/advs.202413674↗
- Paper VDR promotes pancreatic cancer progression in vivo by activating CCL20-mediated M2 polarization of tumor associated mac… DOI 10.1186/s12964-024-01578-x↗
- Paper Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreati… DOI 10.1093/oncolo/oyae207↗
- Changjie Lou · 3 shared papers, 2022–2025 · strength 0.50
- Paper TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1-Mediated Arachidonic A… DOI 10.1002/advs.202413674↗
- Paper Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreati… DOI 10.1093/oncolo/oyae207↗
- Paper HOXB9 blocks cell cycle progression to inhibit pancreatic cancer cell proliferation through the DNMT1/RBL2/c-Myc axis. DOI 10.1016/j.canlet.2022.215595↗
- Zhiwei Li · 2 shared papers, 2025–2026 · strength 0.48
- Yanqiao Zhang · 3 shared papers, 2022–2024 · strength 0.47
- Paper VDR promotes pancreatic cancer progression in vivo by activating CCL20-mediated M2 polarization of tumor associated mac… DOI 10.1186/s12964-024-01578-x↗
- Paper Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreati… DOI 10.1093/oncolo/oyae207↗
- Paper HOXB9 blocks cell cycle progression to inhibit pancreatic cancer cell proliferation through the DNMT1/RBL2/c-Myc axis. DOI 10.1016/j.canlet.2022.215595↗
- Zhiwei Li · 2 shared papers, 2024 · strength 0.34
- Paper VDR promotes pancreatic cancer progression in vivo by activating CCL20-mediated M2 polarization of tumor associated mac… DOI 10.1186/s12964-024-01578-x↗
- Paper Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreati… DOI 10.1093/oncolo/oyae207↗
- Zhigang Ma · 1 shared paper, 2026 · strength 0.27
- Dan Wang · 1 shared paper, 2024 · strength 0.16
- Tongsen Zheng · 1 shared paper, 2024 · strength 0.16
- Yang Yao · 1 shared paper, 2022 · strength 0.13
- Lin Fang · 1 shared paper, 2022 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.